News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Anders Jack
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/21/2023 |
4
| Anders Jack (CFO) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 665 shares
@ $21.78, valued at
$14.5k
|
|
| 12/21/2022 |
4
| Anders Jack (CFO) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 658 shares
@ $22.9405, valued at
$15.1k
|
|
| 09/21/2022 |
4
| Anders Jack (CFO) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 449 shares
@ $19.0426, valued at
$8.6k
|
|
| 09/02/2022 |
4
| Anders Jack (CFO) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 35,000 options to buy
@ $21.61, valued at
$756.4k
|
|
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/21/2021 |
4
| Anders Jack (See Remarks) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 166 shares
@ $30.02, valued at
$5k
|
|
| 06/22/2021 |
4
| Anders Jack (See Remarks) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 160 shares
@ $34.1241, valued at
$5.5k
|
|
| 03/08/2021 |
4
| Anders Jack (See Remarks) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Granted 7,400 shares
@ $0
Granted 25,900 options to buy
@ $42.45, valued at
$1.1M
|
|
| 10/15/2020 |
4
| Anders Jack (See Remarks) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 10,000 shares
@ $44, valued at
$440k
Exercised 10,000 options to buy
@ $2.68, valued at
$26.8k
|
|
| 10/08/2020 |
4
| Anders Jack (See Remarks) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Sold 10,000 shares
@ $40, valued at
$400k
Exercised 10,000 options to buy
@ $2.68, valued at
$26.8k
|
|
|
|